SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-15-079966
Filing Date
2015-11-18
Accepted
2015-11-18 16:33:06
Documents
7
Period of Report
2015-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q a15-23087_110q.htm 10-Q 1045623
2 EX-10.1 a15-23087_1ex10d1.htm EX-10.1 104875
3 EX-10.2 a15-23087_1ex10d2.htm EX-10.2 100782
4 EX-10.3 a15-23087_1ex10d3.htm EX-10.3 96281
5 EX-31.1 a15-23087_1ex31d1.htm EX-31.1 11044
6 EX-31.2 a15-23087_1ex31d2.htm EX-31.2 11026
7 EX-32.1 a15-23087_1ex32d1.htm EX-32.1 7826
  Complete submission text file 0001104659-15-079966.txt   1378455
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 151241156
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences